Mark Ragosa Biography and Net Worth

CFO of Kiniksa Pharmaceuticals International

Mark joined Kiniksa prior to the company’s initial public offering in 2018. Mark oversees financial operations, investor relations, and information technology. Before his promotion to Chief Financial Officer in 2021, Mark served as the Vice President of Investor Relations and Finance. He joined Kiniksa from Ironwood Pharmaceuticals, where he was a member of the investor relations team. Prior to Ironwood, Mark was a vice president in the equities division at Goldman Sachs, where he built strategic relationships with key hedge fund and mutual fund companies and helped raise capital for private and public companies. Mark also held roles of increasing responsibility within the equities divisions of Morgan Stanley and Bank of America Securities. Mark has over 20 years of experience in the financial services and life sciences industries. He has a strong understanding of institutional investor needs as well as an extensive knowledge of finance and equity markets.

Mark holds a BA in government and history from Bowdoin College and is a Chartered Financial Analyst.

What is Mark Ragosa's net worth?: The estimated net worth of Mark Ragosa is at least $1.27 million as of November 12th, 2025. Mr. Ragosa owns 31,086 shares of Kiniksa Pharmaceuticals International stock worth more than $1,274,215 as of December 4th. This net worth approximation does not reflect any other assets that Mr. Ragosa may own. Learn More about Mark Ragosa's net worth.
How old is Mark Ragosa?: Mr. Ragosa is currently 50 years old. There are 4 older executives and no younger executives at Kiniksa Pharmaceuticals International. The oldest executive at Kiniksa Pharmaceuticals International is Dr. John F. Paolini FACC, M.D., Ph.D., Senior VP & Chief Medical Officer, who is 59 years old. Learn More on Mark Ragosa's age.
How do I contact Mark Ragosa?: The corporate mailing address for Mr. Ragosa and other Kiniksa Pharmaceuticals International executives is CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11. Kiniksa Pharmaceuticals International can also be reached via phone at (781) 431-9100 and via email at [email protected]. Learn More on Mark Ragosa's contact information.
Has Mark Ragosa been buying or selling shares of Kiniksa Pharmaceuticals International?: Over the course of the past ninety days, Mark Ragosa has sold $818,806.00 of Kiniksa Pharmaceuticals International stock. Most recently, Mark Ragosa sold 19,900 shares of the business's stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $40.94, for a transaction totalling $814,706.00. Following the completion of the sale, the chief financial officer now directly owns 31,086 shares of the company's stock, valued at $1,272,660.84. Learn More on Mark Ragosa's trading history.
Who are Kiniksa Pharmaceuticals International's active insiders?: Kiniksa Pharmaceuticals International's insider roster includes Thomas Malley (Director), Michael Megna (Group Vice President of Finance and Chief Accounting Officer), Ross Moat (Executive Vice President, Chief Commercial Officer), John Paolini (Executive Vice President, Chief Medical Officer), Sanj Patel (CEO and Chairman of the Board), Barry Quart (Director), Mark Ragosa (CFO), and Eben Tessari (https://monarchcasino.com/corporategovernance_boardofdirectors.asp). Learn More on Kiniksa Pharmaceuticals International's active insiders.
Are insiders buying or selling shares of Kiniksa Pharmaceuticals International?: In the last year, insiders at the sold shares 57 times. They sold a total of 1,575,162 shares worth more than $51,430,265.98. The most recent insider tranaction occured on November, 26th when COO Eben Tessari sold 200 shares worth more than $8,578.00. Insiders at Kiniksa Pharmaceuticals International own 53.5% of the company. Learn More about insider trades at Kiniksa Pharmaceuticals International.
Information on this page was last updated on 11/26/2025.

Mark Ragosa Insider Trading History at Kiniksa Pharmaceuticals International

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/12/2025	Sell	19,900	$40.94	$814,706.00	31,086
10/28/2025	Sell	100	$41.00	$4,100.00	31,086
8/4/2025	Sell	18,889	$32.89	$621,259.21	27,009
6/3/2025	Sell	18,299	$28.80	$527,011.20	27,009
4/30/2025	Sell	21,254	$26.95	$572,795.30	27,009
3/19/2025	Sell	8,879	$23.10	$205,104.90	23,382
3/17/2025	Sell	11,464	$23.10	$264,818.40	23,382
3/12/2025	Sell	36,372	$22.25	$809,277.00	22,958
12/5/2024	Sell	1,123	$21.25	$23,863.75	22,958
12/3/2024	Sell	8,969	$21.45	$192,385.05	22,958
7/23/2024	Sell	24,248	$24.79	$601,107.92	19,253
1/3/2024	Sell	12,000	$20.00	$240,000.00	15,632

Mark Ragosa Buying and Selling Activity at Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International Company Overview

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Today's Range

Now: $40.99

$39.79

$41.48

50 Day Range

MA: $39.46

$36.49

$42.71

2 Week Range

Now: $40.99

$17.82

$42.98

Volume

331,068 shs

Average Volume

299,683 shs

Market Capitalization

$3.11 billion

P/E Ratio

91.09

Dividend Yield

N/A

Beta

0.02

Mark Ragosa Biography and Net Worth

What is Mark Ragosa's net worth?

How old is Mark Ragosa?

How do I contact Mark Ragosa?

Has Mark Ragosa been buying or selling shares of Kiniksa Pharmaceuticals International?

Who are Kiniksa Pharmaceuticals International's active insiders?

Are insiders buying or selling shares of Kiniksa Pharmaceuticals International?